Cellebrite DI Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-81.1	116.11	70.43	-9.34	-10.04
Depreciation & Amortization	10.01	9.19	7.01	5.88	4.08
Share-Based Compensation	19	13.71	6.48	7.27	12.76
Other Operating Activities	154.15	-118.44	-47.87	62.7	9.33
Operating Cash Flow	102.06	20.58	36.05	66.51	16.13
Operating Cash Flow Growth	395.98%	-42.92%	-45.79%	312.26%	-
Capital Expenditures	-7.92	-9.09	-8.11	-6.18	-6.21
Acquisitions	0	0	-20	-15.05	0
Change in Investments	-14.62	-82.15	73.34	14.78	-40.51
Investing Cash Flow	-22.54	-91.23	45.23	-6.45	-46.72
Dividends Paid	0	0	-100	-10	-25
Share Issuance / Repurchase	2.62	1.34	29.3	-0.09	-0.67
Other Financing Activities	19.14	12.63	2.31	1.49	101.21
Financing Cash Flow	21.77	13.97	-68.4	-8.59	75.54
Exchange Rate Effect	0.59	-1.64	-0.75	0.7	-0.07
Net Cash Flow	101.28	-56.68	12.88	51.47	44.95
Free Cash Flow	94.14	11.49	27.94	60.33	9.92
Free Cash Flow Growth	719.18%	-58.87%	-53.69%	507.91%	-
Free Cash Flow Margin	28.96%	4.25%	11.35%	30.95%	5.77%
Free Cash Flow Per Share	0.49	0.06	0.19	0.49	0.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).